AS FAR AS THE OFFICIAL COMPENDIA, the-United States Pharmacopeia and the National Formulary, are concerned, the Report from the Drug Bipequivalence Study Panel to the Office of Technology Assessment of the Congress of the United States is grievously frustrating.
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tinguished physicians, two biopharmaceutists, and a statistician, supported by a contractor who employed a pharmacist as project director, could write so unsophisticatedly on drug production, quality assurance, and regulatory control should be of concern to us all. If these people, each distinguished in his own field, are so naive, then what does the average practitioner of medicine or pharmacy understand about drug quality and its control? One example from the Panel's Report will suffice:
Newer Techniques in C?mpendial Methods (p. 26) "In the 1880's, the pharmaceutical industry became the primary supplier of drug products and accepted responsibility for standardizing the products. However, the compendial tests for strength and purity still retained their basic simplicity, requiring minimal instrumentation and analytical skill, so that a pharmacist could still perform the assays.
"Reliance on simple approaches to specifications of materials and control of quality persists to this day. These shortcomings in present-day assessment of drugs particularly pertain to the tests for identity, purity and potency that form the legal basis upon which compliance or lack of compliance is established (Federal Food, Drug, and Cosmetic Act). In some cases, physical tests and assay procedures of much greater sensitivity than those in the compendia are known; many of these tests are fully automated."
"Persists to this day!" Really, is there one pharmacy in the entire country that has high-pressure liquid chromatography, gas liquid chromatography, X-ray diffraction spectrophotometry, atomic absorption spectrophotometry, and spectrophotofluorometry equipment -each needed for one or more test procedures in the forthcoming USP XIX or NF XIV! It seems clear that if the practitioners of pharmacy, who traditionally have the USP and NF on hand, do not pay more attention to drug quality characteristics and the nation's drug quality control system, they will be mere puppets swaying in the propaganda puffs of the industry and government agencies, each of which has its own vested interests to protect.
The recent merger of the USP and NF leaves the compendia still under the control of the professions. Now is the time to reassert the benefits to drug quality assurance that can be provided to the citizenry by having concerned and informed professionals responsible for the drugs dispensed, as well as for manufacturing them and setting standards for them. WILLIAM M. HELLER, Ph.D., is Executive Director of The United States Pharmacopeial Convention Inc. publishers of the United States Pharmacopeia. ' ' AUG 74 461
